

**SANGAM HEALTH CARE PRODUCTS LIMITED**

205 &amp; 206, AMARCHAND SHARMA COMPLEX, S.P. ROAD, SECUNDERABAD

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2018**
**(Rs.In Lakhs)**

	Particulars	Quarter Ended			Year to Date figures for current period
		30/06/2018	31.03.2018	30/06/2017	ended 31/03/2018
		Unaudited	Audited	Unaudited	Audited
<b>1</b>	Income from Operations				
(a)	Net Sales/Income from Operations (Net of Excise duty)	504.11	478.44	443.24	2,088.90
(b)	Other Operating Income	-	1,840.52	-	1,841.02
	<b>Total Income from Operations</b>	<b>504.11</b>	<b>2,318.96</b>	<b>443.24</b>	<b>3,929.92</b>
<b>2</b>	Expenditure				
	(a) Cost of Raw material consumed	288.02	344.38	212.79	1,177.57
	(b) Purchase of stock-in-trade				
	(c) Change in inventories of Finished Goods Works-in Progress and Stock in Trade	(15.00)	367.61	(38.88)	327.66
	(d). Employees Benefit Expenses	130.02	134.25	111.89	480.16
	(e). Depreciation and Amortization Expenses	38.07	38.15	38.14	152.28
	(f). Other Expenditure	172.45	272.78	221.10	899.24
	<b>Total expenses</b>	<b>613.56</b>	<b>1,157.17</b>	<b>545.04</b>	<b>3,036.91</b>
<b>3</b>	Profit from Operations before Other Income, Financial Cost and Exceptional Items (1-2)	(109.45)	1,161.79	(101.80)	893.01
<b>4</b>	Other Income	-		-	0.00
<b>5</b>	Profit before Finance Cost and Exceptional Items (3+4)	(109.45)	1,161.79	(101.80)	893.01
<b>6</b>	Finance Cost	-	-	-	0.00
<b>7</b>	Profit after Financial Cost but before Exceptional Items (5-6)	(109.45)	1,161.79	(101.80)	893.01
<b>8</b>	Exceptional Items				
<b>9</b>	<b>Profit / (Loss) from Ordinary Activities before tax (7+8)</b>	<b>(109.45)</b>	<b>1,161.79</b>	<b>(101.80)</b>	<b>893.01</b>
<b>10</b>	Current tax	0	7.36	0	7.36
	Deferred tax	0	148.28	0	148.28
<b>11</b>	<b>Net Profit (+)/Loss(-) from Ordinary Activities After Tax (9-10)</b>	<b>-109.45</b>	<b>1006.15</b>	<b>-101.80</b>	<b>737.37</b>
<b>12</b>	Paid up equity share capital (no of shares) (face value of the share Rs.10/-)	1486.07	1486.07	1486.07	1,486.07
<b>13</b>	Reserves excluding revaluation reserves	NIL	NIL	NIL	NIL
<b>14</b>	Earning Per Share (EPS)	(0.07)	0.677	(0.07)	0.4962
	a) Basic and diluted Eps before Extraordinary (not to be annualized)				
	b) Basic and diluted Eps after Extraordinary				

	(not to be annualized)				
	<b>A. PARTICULARS OF SHAREHOLDING</b>				
1	Public Shareholding				
	- No of Shares	3,865,200	3,865,200	3,865,200	3,865,200
	- Percentage of share holding	26.00	26.00	26.00	26.01%
2	<b>Promoters and promoter group</b>				
	<b>Share holding</b>				
	<b>a) Pledged/Encumbered</b>	NIL	NIL	NIL	NIL
	- Number of Shares				
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)				
	- Percentage of Shares (as a % of the total sharecapital of the company)				
	<b>b) Non - encumbered</b>				
	-- Number of Shares	10995500	10995500	10995500	10,995,500
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	73.99%	73.99%	73.99%	73.99%
	- Percentage of shares (as a % of the total share capital of the company)				
	<b>B.INVESTORS COMPLIANTS</b>				
	pending at the beginning of the quarter	Nil	Nil	Nil	Nil
	Received during the quarter	Nil	Nil	Nil	Nil
	Disposed of during the Quarter	Nil	Nil	Nil	Nil
	Remaining unresolved at the end of the quarter	Nil	Nil	Nil	Nil

Note :

- 1 The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at the meeting held on August,13, 2018
- 2 The Limited Review of the Financials has been carried out by the Statutory Auditors of the Company in terms of of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The Company has adopted Indian Accounting Standards ("Ind AS") effective April 01, 2017 and accordingly, the financial results for the quarter ended June 30, 2018 have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 "Interim Financial reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular CIR/CFD/FAC/62/2016 dated July 05, 2016. The results for the comparative quarter ended June 30, 2017 have been restated in accordance with Ind AS. After adoption of Ind AS the financial results for the quarter ended June 30 2018 have not been audited or reviewed by the auditors and are compiled by the management after exercising necessary due diligence to ensure that these give a true and fair view of the company's affairs
- 4 The Segment reporting as defined in Accounting Standiand-17 is not aplicable, as the opeation of the Company are related to one Segment
- 5 Previous Accounting period's figures have been grouped/regrouped wherever considered necessary.
- 6 The Reconciliation of Net Profit reported under Indian GAAP for the quarter ended June 30, 2017 with Ind AS is given below

Net profit under previous GAAP	-109.45	-101.8
Net profit for the period under IND AS	-109.45	-101.8

Place : Secunderabad

Date:August 13, 2018

For Sangam Health Care Products Limited

Chairman and Managing Director





**LIMITED REVIEW REPORT**

To.  
The Board of Directors.  
**Sangam Health Care Products limited**


We have reviewed the accompanying statement of unaudited financial results of Sangam Health Care Product Limited, Secunderabad for the quarter ended 30th June, 2018. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410. "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express any audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2004 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.R. Shekher & Co.,  
Chartered Accountants  
FRN : 010828S



  
**Rajashekhar Kaparti**  
Partner  
Membership No. 214810

Place: Hyderabad  
Date: 13-08-2018